Barclays lowered the firm’s price target on Oscar Health (OSCR) to $11 from $17 and keeps an Underweight rating on the shares. The firm reduced estimates through 2027 following the earnings report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health raises FY25 revenue view to $12.0B-$12.2B from $11.2B-$11.3B
- Oscar Health sees Q2 net loss $228M
- Oscar Health downgraded to Sell from Neutral at UBS
- Oscar Health downgraded to Neutral from Overweight at Piper Sandler
- Option traders moderately bearish in Oscar Health with shares down 4.67%